Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Liver Diseases × Ribavirin × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 3 Lymphoma, Follicular 3 Lymphoma, Mantle-Cell 2 Wilms Tumor 1 Testicular Neoplasms 1 Teratoma, Testicular 1 Teratoma 1 Seminoma 1 Recurrence 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroblastoma 1 Neoplasms 1 Multiple Myeloma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Liver Diseases 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, Hairy Cell 1 Infections 1 Hodgkin Disease 1 Hepatitis C 1 Endodermal Sinus Tumor 1 Dendritic Cell Sarcoma, Interdigitating 1

Interventions

repotrectinib 1 ozanimod 1 ledipasvir, sofosbuvir drug combination 1 belinostat 1 Sofosbuvir 1 Ribavirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02717949 2019-01-08

Optimal

University of Texas Southwestern Medical Center

Phase 4 Terminated

Hepatitis C, Liver Diseases, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡